HTG2014-Section-Header-publications

Categories

Filter by Topics

1L therapy; bispecific antibodies 478P TA-ness AACR2023 ABC- type ADCC Gene Alteration adolescents AI alcohol consumption ALK alzheimer's Angiogenesis angiosarcoma Anti-TNF Alpha Therapy antibody drug conjugates antiEGFR aplastic anemia AA Apoptosis apoptosis appendiceal neoplasms Asthma Autocrine Signaling Autoimmune Disorder Avelumab B Cells B-accute lyphoblastic leukemia B-ALL B-accute lyphoblastic seukemia B-ALL B-cell lymphoma bacterial vaginosis BCL2A1 BCL6 benign bile acids Biofluid Biology of neoplasia biomarker Biomarker Biomarker Analysis Biomarker Discovery Biomarker Validation biomarkers Biomarkers Bladder Bladder Cancer Bladder cancer Blastic plasmacytoid dandritic cell neoplasm BPDCN blastoid morphology blindness Blood bone Brain breast cancer Breast Cancer Breast Milk Breast milk Burkitt lymphoma cancer genetics Cancer Genomics cancer therapy CAR T cell therapy CAR-T-cells Cardiovascular Disease Castleman Disease CD10 CD3 CD8 CDK CDK46 inhibitors CDKN1A CDKN2A mutation Cell Free Plasma Cells Cerebrospinal Fluid cervix Cetuximab Chemokines chemotherapy Childhood Atopic Dermatitis children chronic kidney disease Chronic Obstructive Pulmonary Disease Circulating miRNAs circulating tumor Circulating tumor cells classifications clinical trial Clinical Trial cMET cognition cold tumor Colon Colon cancer Colorectal cancer Comparative Study Comparison study computational toxicology Core Needle Biopsy cornea COVID-19 cultivated limbal epithelial cells Clec Custom mRNA custom panel CXCL12 cyclic AMP‑dependent transcription factor ATF‑4 Cytokine Cytokines Cytotoxic T Cells cytotoxicity dementia Dementia Developmental Immunotherapy Developmental Therapeutics Diabetes diabetic nephropathy Differential Expression Differential Gene Expression Analysis Diffuse Large B-Cell Lymphoma diffuse large B-cell lymphoma DLBCL DLBCL COO DNA damage‑inducible transcript 3 protein DNA lymphoma Drug Response Drug Safety Drug sensitivity Drug Targets Drug-induced Liver Injury dysbiosis Dysplasia ear Efficacy EGFR Muatations EHE cancer EMT Encephalophy end stage kidney disease Endothelial cell EPCORE NHL-1 epidemiology epidermal growth factor receptor EGFRHER Epigenetics epigenomics Epithelial–mesenchymal plasticity Epstein-Barr ERBB3 Esophageal Cancer estrogen and progesteron receptors estrogen receptor 1 ESR1 exosome Exosomes extracellular miRNAs Extracellular Vesicles Extracellular Vesicles Evs extraction-free RNA workflow Fabry Disease farnesoid X receptorcholesterol Feasibility female reproductive tract FFPE FGF Ligand Trap FGFR fibroblast growth factor receptor 4 Fibrous Tumors FOLFOX7 Follicular lymphoma gastrointestinal cancer GEIS Gene Expression gene expression Gene expression analysis gene expression profiling Gene Expression Profiling gene expression signature Gene Fusions Gene Signature Analysis Genetic Polymorphism Genitourinary cancer Glioblastoma Tumors glucocorticoid receptor NR3C1 HARMONIA clinical trial HCC Head and Neck Cancer Head and neck cancer Heart hematologic or solid tumors hepatocellular carcinoma HER HER-2 HER2 HER2- Heterogeneity Histone Deacetylase Inhibitors histone methyltransferase HLA-E Homing hot tumor HPV HR+ HTG EdgeSeq HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq Custom Assays HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq DLBCL Cell of Origin Panel HTG EdgeSeq DLBCL-COO-CE-IVD HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immune Response Panel HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Immuno-Oncology Panel HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq Lymphoma Panel HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq miRNA Whole Transcriptome Panel HTG EdgeSeq miRNA WTA HTG EdgeSeq Mouse mRNA Tumor Response Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq PATH Assay HTG EdgeSeq Path Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq Precision Immunol-Oncology Panel HTG EdgeSeq System HTG EdgeSeq System Oncology Biomarker Panel HTG EdgSeq Immuno-Oncology Assay HTP ibrutinib Ibrutinib Immune Cells Immune Checkpoint Inhibitors Immune microenvironment Immune Related Genes Immune Response Immune System Immune Tolerance Immune-related Colitis Immuno-Oncology immuno-oncology agents immunohistochemistry IHC Immunologically hot tumours IMMUNOSARC immunoscore Immunotherapy immunotherapy Inflammation inhibitor Insulin Resistance Integrins Intrinsic subtypes inverted papilloma IOA- 244 IOA-244 IRF4 IRP IRS-1 ISG JAVELINE bladder Juvenile Arthritis Kidney kikuchi-fujimoto disease KRAS Kruppel-like factor 5 Lactobacillus crispatus LAG3+ Limb ischemia limbal stem cell deficiency LSCD Liposarcoma Liquid Biopsy liver Liver liver disease liver steatosis liver tissue Lung Lung cancer lungs Lupus Lymph Node Metastasis lymphatic Lymphocytes Lymphoid Neoplasia lymphoma Lymphoma lymphomas Machine Learning machine learning malignancy sinonasal malignant mCRC Mechanism of Action melanoma Melanoma Mesothelioma MET metastatic breast cancer MBC metastatic colorectal cancer CRC Method Comparison MIBC Microenvironment microRNA MicroRNA miR-122-5p miR-3937 miRNA miRNA WTA miRNA-375 Molecular Characterization molecular subtypes Mouse Mouse mRNA mouse mRNA TRP mRNA mRNA custom mTOR pathway mTOR signaling multi-omics multiple myeloma Multiple Myeloma MUM1 Muscle Muscle-invasive bladder cancer mutation analysis Mutations MYC NAFLD Nash and Fibrosis native African men Natural Killer Cells Nature Neoantigens Nestin+ Neuroendocrine Tumor Neurologic nivolumab NKG2A Non-alcoholic fatty liver disease non-Hodgink Lymphoma non-Hodgkin Lymphoma Non-Hodgkin lymphoma NHL Non-small cell lung cancer Novel Therapeutic Targets NTRK1 nuclease protection assay Obesity obesity OBP Oesophageal Adenocarcinoma Oncology Oncology-Biomarker OPSCC Optical imaging Oral Cancer Oral cancer Oral cavity Oral lesion Oral Squamous Cell Carcinoma oral squamous cell carcinoma Oropharyngeal Cancer OSCC Osteoarthritis Osteoclast Ovarian cancer palbociclib PALLET PALOMA PALOMA-2 PAM50 Predictive biomarkers Pan-Cancer PanB Pancreas Pancreatic Cancer pancreatic ductal adenocarcinoma PDAC Paralysis Parkinson's Disease Partial EMT Pathogenesis pathophysiology Pathway analysis Pathway Analysis Patient Stratification PAXgene PBMCs PCA Cell Lines PD-1 PD-L1 PDX model PEARL PENELOPE-B PFAS PFNA PFOS Phase III PHOENIX trial PI3K PI3K inhibitors PIK3CA mutation PIP Placenta placenta Plasma Plasma miRNAs Platform Comparison PMAIP1 population based Precision medicine Precision oncology predictive biology Predictive Biomarkers Predictive Modeling Prevotella bivia Programmed cell death protein 1 Progression free-survival progression of renal failure Prostate prostate cancer Prostate Cancer prostate genomics Protein Protein Interaction network qNPA qPCR R-CHOP race disparities Radioimmunotherapy RAS Rbsig Rearrangements Refractory DLBCL Relapsed DLBCL Renal Cell Carcinoma renal cell carcinoma Renal Disease Reproductive Response rate RET Reveal Rhabdomyosarcoma RMS Rheumatoid Arthritis Risk Score ROS1 safety sarcoma Sarcoma SARS-CoV-2 scoring system Sequencing Serum Signaling Inhibitors Signaling Pathways Signature Validation Signatures single cell Single-cell RNA Sinonasal Carcinoma Skin soft tissue sarcoma SPECS Lung Consortium Squamous cell carcinoma squamous cell carcinoma STAT6 pathway STD Sub-typing surface plasmon Surveillance Survival Outcomes Survival plots Synovial Fluid Synovial Sarcoma synthetic miRNA T cells T-Cell T-cells targeted therapeutics Technology Comparison Testicular cancer Therapeutic Response Therapeutic targets Thymic Carcinoma Thyroid Cancer Tislelizumab tislelizumab TMB TME tomentosin Toxicity TP53 mutation transcriptome Transcriptome transcriptome profile transcriptome profiling Translational Medicine Transplantation Treatment Outcome Treatment Stratification Treatment Targets Trichomonas vaginalis Triple Negative Breast CancerTNBC Tumor Biology Tumor Heterogeneity Tumor Immunobiology Tumor infiltrating lymphocytes tumor microenvironment Tumor Microenvironment Urine Urothelial carcinoma Uterus vagina VEGFR vestibular schwannoma VS virus Waldeyer's ring Wound healing Xenograft Tissue Zanubrutinib Zanubrutinlb ZEB1

2020

Acalbrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase lb/ll Single Arm Study

Davies, A., et al. Acalbrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase lb/ll Single Arm Study. Blood Journal 2020 NOV 5 136 (S1):88-89.

View External Link

Neratinib plus Cetuximab in Quadruple WT (KRAS, NRAS, BRAF, PIK3ca) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study

Jacobs, S. A., et al. Neratinib plus Cetuximab in Quadruple WT (KRAS, NRAS, BRAF, PIK3ca) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study. Clinical Cancer Research 2020 NOV 17 DOI: 10.1158/1078-0432.CCR-20-1831

View External Link

Ileal transcriptomic analysis in pediatric Crohn's disease reveals IL17-and NOD-signaling expression signatures in treatment-naïve patients and identifies epithelial cells driving differentially expressed genes

Ashton, J. et al. Ileal transcriptomic analysis in pediatric Crohn's disease reveals IL17-and NOD-signaling expression signatures in treatment-naïve patients and identifies epithelial cells driving differentially expressed genes. Journal of Crohn's anc Colitis. 2020 NOV 24  https://doi.org/10.1093/ecco-jcc/jjaa236 

Download pdf 6.4MB

Potential Mechanisms of Resistance Identified Through Analysis of Multiple Biomarkers in Immune-Hot Non-Responders with Non-small Cell Lung Cancer Treated with Tislelizumab

Desai, J., et al. Potential Mechanisms of Resistance Identified Through Analysis of Multiple biomarkers in Immune-Hot Non-Responders with Non-small Cell Lung Cancer Treated with Tislelizumab. Poster presented at Society for Immunotherapy of Cancer Virtual Congress. 2020 Nov 9-14

Download pdf 386KB

Comparative analysis of gene expression platforms for cell-of-origin classification of diffuse large B-cell lymphoma shows high concordance

Ahmed, S., et al. Comparative analysis of gene expression platforms for cell-of-origin classification of diffuse large B-cell lymphoma shows high concordance. Br J Haematol. 2020 Nov 29. doic 10.1111/bjh.17246. Online ahead of print

Download pdf 943KB
View External Link

Multi-Omics and Informatics Analysis of FFPE Tissues Derived from Melanoma Patients with Long/Short Responses to Anti-PD1 Therapy Reveals Pathways of Response

Garg, S. K., et al. Multi-Omics and Informatics Analysis of FFPE Tissues Derived from Melanoma Patients with Long/Short Responses to Anti-PD1 Therapy Reveals Pathways of Response. Cancers 2020, 12, 3515; doi:10.3390/cancers1213515

Download pdf 3.3MB

Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine

Lodhi, N., et al. Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine. Oncotarget 2020(11):44, 4055-4073. 

Download pdf 3.6MB

Page last updated May 22, 2023